However, she also noted that significant efficacy was not demonstrated in the small subgroup of elderly patients, where a pooled analysis failed to reach statistical significance [ 33 ].
← all excerpts
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews.
1
—
—